In a 58‑year‑old woman with hypertension, gastroesophageal reflux disease, hyperlipidemia, a prior atherosclerotic stroke, and type 2 diabetes (C‑peptide 2.7 ng/mL) currently on basal insulin Lantus (insulin glargine) 14 U with a 1‑unit‑per‑8‑g carbohydrate correction factor, which glucose‑lowering agent should be added first: a DPP‑4 inhibitor, an SGLT‑2 inhibitor, or a GLP‑1 receptor agonist?

Add a GLP-1 Receptor Agonist First

In this 58-year-old woman with type 2 diabetes and a prior atherosclerotic stroke, add a GLP-1 receptor agonist (liraglutide, semaglutide, or dulaglutide) immediately—this is the only class proven to reduce recurrent stroke risk in patients with established cerebrovascular disease. 1

Why GLP-1 Receptor Agonists Are the Priority

Stroke-Specific Protection

• GLP-1 receptor agonists reduce stroke by 14% (RR 0.86,95% CI 0.77–0.95) in patients with type 2 diabetes, a benefit not seen with SGLT2 inhibitors or DPP-4 inhibitors. 1
• In patients with prior stroke or MI, GLP-1 receptor agonists reduced recurrent major adverse cardiovascular events (MACE) by 14% (HR 0.86,95% CI 0.8–0.92). 1
• SGLT2 inhibitors do not reduce stroke risk (RR 1.12,95% CI 0.93–1.34), and in fact showed a non-significant trend toward increased stroke in some analyses. 1

Guideline-Mandated Recommendations

• Both the 2024 ESC and 2020 ACC explicitly recommend GLP-1 receptor agonists with proven cardiovascular benefit (Class I, Level A) for patients with type 2 diabetes and established atherosclerotic cardiovascular disease, which includes prior stroke. 1
• The 2019 ESC/EASD guidelines state that GLP-1 receptor agonists are recommended to reduce cardiovascular events independent of baseline HbA1c or concomitant glucose-lowering medication. 1
• DPP-4 inhibitors are explicitly not recommended for reducing morbidity or mortality (high strength of evidence). 2

Specific GLP-1 Receptor Agonist Selection

Choose one of these three agents with proven cardiovascular benefit:

• Dulaglutide 0.75 mg subcutaneously weekly, titrate to 1.5 mg weekly after 4 weeks 1
• Liraglutide 0.6 mg subcutaneously daily, titrate by 0.6 mg weekly to 1.2–1.8 mg daily 1, 2
• Semaglutide (injectable) 0.25 mg subcutaneously weekly, titrate to 0.5 mg at week 4, then 1.0 mg at week 8 1, 2

Start at the lowest dose and follow labeling instructions for dose titration to minimize gastrointestinal side effects (nausea, vomiting). 1

When to Add SGLT2 Inhibitor Second

Add an SGLT2 inhibitor (empagliflozin, canagliflozin, or dapagliflozin) 3 months after initiating the GLP-1 receptor agonist if:

• The patient has hypertension (which she does), as SGLT2 inhibitors provide additional blood pressure reduction of 3–5 mmHg. 1, 3
• You want to reduce heart failure hospitalization risk by 36% (RR 0.64,95% CI 0.54–0.77). 1
• The patient's eGFR is ≥25 mL/min/1.73 m² for renal protection. 1, 3

The cardiovascular and renal benefits of GLP-1 receptor agonists and SGLT2 inhibitors are additive and independent—effects remain consistent whether or not the patient is on the other drug class. 4

Why Not DPP-4 Inhibitors

• DPP-4 inhibitors are cardiovascular-neutral (RR 1.0,95% CI 0.94–1.06 for MACE) and provide no mortality benefit. 1, 2
• They offer weaker HbA1c reduction compared to GLP-1 receptor agonists (approximately 0.5% less reduction). 5
• Saxagliptin specifically increases heart failure hospitalization risk and is contraindicated in patients at risk for heart failure. 1
• The American College of Physicians explicitly states DPP-4 inhibitors are not recommended for reducing morbidity or all-cause mortality (high strength of evidence). 2

Insulin Adjustment

• Reduce basal insulin (Lantus) dose by 10–20% when adding the GLP-1 receptor agonist to prevent hypoglycemia. 3
• Monitor blood glucose for 2–4 weeks after initiation. 3
• The 1:8 carbohydrate ratio for mealtime correction can remain unchanged initially but reassess after 3 months. 1

Critical Monitoring

• Reassess HbA1c within 3 months of adding the GLP-1 receptor agonist to ensure adequate glycemic control. 2
• Monitor for gastrointestinal side effects (nausea, vomiting, diarrhea) during dose titration—these typically resolve within 4–8 weeks. 1, 2
• Check for contraindications: personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2. 6
• The patient's GERD may transiently worsen due to delayed gastric emptying; consider proton pump inhibitor optimization. 6

Common Pitfalls to Avoid

• Do not start with a DPP-4 inhibitor in a patient with established atherosclerotic cardiovascular disease—this represents a missed opportunity for proven mortality reduction. 2
• Do not delay GLP-1 receptor agonist initiation based on current HbA1c or glycemic control—cardiovascular benefits are independent of glucose-lowering effects. 1
• Do not use SGLT2 inhibitors as monotherapy for stroke prevention—they do not reduce stroke risk and may increase it. 1
• Do not combine DPP-4 inhibitors with GLP-1 receptor agonists—they share the same incretin pathway and provide no additive benefit. 5